The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal

Simply Wall St.07-15

Summit Therapeutics recently announced it has sold its investigational Phase III precision antibiotic ridinilazole to Toronto-based Biossil Inc., receiving a US$500,000 upfront payment, with up to US$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651343025?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-15 14:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651343025","market":"sg","top_or_hot":-1,"title":"The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal","media":"Simply Wall St.","content":"<div>\n<p>Summit Therapeutics recently announced it has sold its investigational Phase III precision antibiotic ridinilazole to Toronto-based Biossil Inc., receiving a US$500,000 upfront payment, with up to US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/the-bull-case-for-summit-therapeutics-smmt-could-change-foll-2\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-15 14:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/the-bull-case-for-summit-therapeutics-smmt-could-change-foll-2><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summit Therapeutics recently announced it has sold its investigational Phase III precision antibiotic ridinilazole to Toronto-based Biossil Inc., receiving a US$500,000 upfront payment, with up to US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/the-bull-case-for-summit-therapeutics-smmt-could-change-foll-2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/the-bull-case-for-summit-therapeutics-smmt-could-change-foll-2","article_id":"2651343025","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/the-bull-case-for-summit-therapeutics-smmt-could-change-foll-2","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2651343025","pubTimestamp":1784097092,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Summit Therapeutics recently announced it has sold its investigational Phase III precision antibiotic ridinilazole to Toronto-based Biossil Inc., receiving a US$500,000 upfront payment, with up to US$104.5 million in potential regulatory and commercial milestones plus tiered royalties on any future net sales.\nThis agreement effectively reshapes Summit’s pipeline focus toward its oncology programs while adding a new potential source of milestone income and royalties.\nWe’ll now examine how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SMMT":"Summit Therapeutics PLC"},"translate_title":"Ridinilazole 出售和特许权使用费交易后，Summit Therapeutics (SMMT) 的牛市情况可能会发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1.5},"content_text":"Summit Therapeutics recently announced it has sold its investigational Phase III precision antibiotic ridinilazole to Toronto-based Biossil Inc., receiving a US$500,000 upfront payment, with up to US$104.5 million in potential regulatory and commercial milestones plus tiered royalties on any future net sales. This agreement effectively reshapes Summit’s pipeline focus toward its oncology programs while adding a new potential source of milestone income and royalties. We’ll now examine how monetizing ridinilazole for milestones and royalties may influence Summit’s existing investment narrative centered on ivonescimab. Uncover the next big thing with 20 elite penny stocks that balance risk and reward.AdvertisementSummit Therapeutics Investment Narrative RecapTo own Summit Therapeutics today, you need to believe that ivonescimab can clear its key regulatory hurdles and translate its broad late stage program into meaningful commercial uptake, despite the company’s lack of revenue and sizable ongoing losses. The ridinilazole sale to Biossil looks financially modest in the near term, and it does not materially change the most important near term catalyst, the ivonescimab BLA review, or the central risks around trial outcomes, cash burn and potential dilution. Among recent announcements, the US FDA’s acceptance of Summit’s BLA for ivonescimab plus chemotherapy in EGFR mutated NSCLC, with a PDUFA date of November 14, 2026, stands out as the key reference point for this ridinilazole deal. While ridinilazole milestones and royalties could offer a longer term funding cushion if development progresses successfully at Biossil, Summit’s core investment case and near term share price drivers remain concentrated in ivonescimab’s regulatory trajectory and clinical data flow. Yet against this opportunity, investors should also weigh how Summit’s continued losses, current lack of revenue and the potential need for future capital raises could... Read the full narrative on Summit Therapeutics (it's free!)Summit Therapeutics' narrative projects $897.3 million revenue and $169.7 million earnings by 2029. This requires revenue to grow from zero and a roughly $1.4 billion earnings increase from -$1.2 billion today.Uncover how Summit Therapeutics' forecasts yield a $28.36 fair value, a 83% upside to its current price.Exploring Other PerspectivesSMMT 1-Year Stock Price Chart Some of the most optimistic analysts were previously modeling US$2.3 billion in 2029 revenue and US$351.0 million in earnings, which is a very different story from the cash burn and single asset risk you see in the consensus view, and this ridinilazole deal is exactly the kind of update that could shift how you weigh those competing narratives over time.Explore 4 other fair value estimates on Summit Therapeutics - why the stock might be worth 24% less than the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Summit Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.Our free Summit Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Summit Therapeutics' overall financial health at a glance.Seeking Other Investments?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Outshine the giants: these 16 early-stage AI stocks could fund your retirement.AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651343025","isCrawlerRequest":true}